Evaluation of Antibacterial and Antiviral Drug Effectiveness in COVID-19 Therapy: A Data-Driven Retrospective Approach

Abstract

The clinical manifestations associated with COVID-19 disease is mainly due to a dysregulated host response related to the overexpression of inflammatory markers. Until recently, only remdesivir had gained FDA approval for COVID-19 hospitalized patients and there are currently no evidence-based therapeutic options or options for prevention of complications that have been established. Some medical treatments such as antivirals, antibacterials, antithrombotics, antipyretics, corticosteroids, interleukin inhibitors, monoclonal antibodies, convalescent plasma, immunostimulants, and vitamin supplements have been utilized. However, there are limited data to support their effectiveness. Hence, this study was attempted to identify and evaluate the effectiveness of antibacterials and antivirals used for COVID-19 using a retrospective cross-sectional approach based on the medical records of adult patients in four hospitals. The number of antibacterials was calculated in defined daily dose (DDD) per 100 bed-days unit. Both mixed-logit regression and analysis of covariance were used to determine the effectiveness of the aforementioned agents in relation to COVID-19 outcome and patients’ length of stay. The model was weighed accordingly and covariates (e.g., age) were considered in the model. Heart disease was found to be the most common pre-existing condition of COVID-19 hospitalized patients in this study. Azithromycin, an antibacterial in the Watch category list, was used extensively (33–65 DDD per 100 bed-days). Oseltamivir, an antiviral approved by the FDA for influenza was the most prescribed antiviral. In addition, favipiravir was found to be a significant factor in improving patients’ COVID-19 outcomes and decreasing their length of stay. This study strongly suggests that COVID-19 patients’ received polypharmacy for their treatment. However, most of the drugs used did not reach statistical significance in improving the patients’ condition or decreasing the length of stay. Further studies to support drug use are needed.

Hubungan Sosiodemografi dengan Hasil Klinis Pasien Covid-19 di RSUD Bengkulu

“…Indonesia sangat terdampak COVID-19 dengan Case Fatality Rate (CFR) sebesar 8,9% pada akhir Maret 2020 (10). Semua rumah sakit di Indonesia mengikuti pedoman nasional untuk diagnosis dan pengobatan pada saat pasien masuk (11). Terdapat 51,9% kasus terkonfirmasi adalah lakilaki dewasa, dan 31,4% kasus terkonfirmasi berusia antara 31-45 tahun, dengan persentase kematian tertinggi pada usia 46-59 tahun sebesar 39,4%, dan 50,5% kasus terkonfirmasi memiliki hipertensi sebagai penyakit penyerta di Indonesia (12).…”